# OnCo record serena-6 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/serena-6/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "serena-6", "NCT04964934" ;
  schema:name "SERENA-6"@en ;
  schema:description "The first trial to change treatment because of a blood test rather than a scan: switching to camizestrant when an ESR1 mutation appeared in the blood delayed progression by seven months."@en ;
  schema:url <https://onco.cc/trials/serena-6/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04964934>, <https://ascopost.com/news/september-2026/fda-approves-camizestrant-combination-regimen-for-locally-advanced-or-metastatic-breast-cancer/>, <https://www.cancernetwork.com/view/fda-odac-no-camizestrant-for-hr-her2-esr1-advanced-breast-cancer> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2021-06-30" ;
  onco:related <https://onco.cc/collections/src-asco-post/>, <https://onco.cc/collections/src-cancer-network/> ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/hr-positive-metastatic-post-cdk46/> ;
  onco:technologies <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:targets <https://onco.cc/targets/estrogen-receptor/> ;
  onco:drugs <https://onco.cc/drugs/camizestrant/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:terms <https://onco.cc/terms/esr1-mutation/>, <https://onco.cc/terms/ctdna/> ;
  onco:people <https://onco.cc/people/nicholas-turner/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-serena-6-n-engl-j-med-2025/> .